Webinars

NOV 16, 2022 7:00 PM PST

Innovation in Science and Technology: Translating Cellular Therapies from Bench to Bedside

Sponsored by: Revvity

C.E. Credits: P.A.C.E. CE ｜ Florida CE

Speakers

Khalid Shah

DIRECTOR, CENTER FOR STEM CELL AND TRANSLATIONAL IMMUNOTHERAPY, BRIGHAM AND WOMEN'S HOSPITAL
BIOGRAPHY
Jean Qiu

Founder and Chief Technology Officer, Nexcelom Bioscience LLC. (PerkinElmer)
BIOGRAPHY

Event Date & Time

Date: November 16, 2022

Time:7:00pm (PST), 10:00pm (EST), 4:00am (CET)

Abstract

Date: November 17, 2022

2:00pm (AEST)

The growth in FDA-approved cell and gene therapy products for the treatment of diseases including cancer is rapid. However, due to the complexity of cancer biology and manufacturing novelties, there are many challenges in developing and producing regenerative medicines.

In this webinar, Dr. Khalid Shah, MS, Ph.D. Vice-Chair of Research Neurosurgery, from BWH, Harvard Medical School, will present strategies for effective development of cellular therapies via gene editing. He will also discuss how to develop and validate relevant tumor models to ensure the clinical translation of therapeutic cells.

In addition, Dr. Jean Qiu, Founder and Chief Technology Officer of Nexcelom Bioscience, will describe how to enable novel technologies for standardizing cell counting and other critical quality attributes throughout the entire regenerative medicine development process.

Learning Objectives

Apply multiple approaches in gene editing and engineering of cells to develop cellular therapies
Build and evaluate relevant tumor models for effective transition from basic research to clinical trial
Enable novel technology to apply ISO standards for developing regenerative medicines

Webinars will be available for unlimited on-demand viewing after live event.

LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.